Hikma to host meet the management and site visit in Columbus, Ohio
London, 17 March 2025 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, will host sell-side analysts and investors at its Columbus, Ohio manufacturing and R&D facility on Thursday 15 May 2025.
Our state-of-the-art 1,000,000 sq. ft. facility produces oral, respiratory and other generic and specialty products for our Generics business and our CMO partners. It is one of Hikma’s four US manufacturing facilities producing a broad range of medicines for US patients and healthcare providers.
Alongside a tour of the facility, Hafrun Fridriksdottir, President of Generics and Dr Bill Larkins, President of Injectables will present on our Generics and Injectables businesses, updating on strategy and our positioning for long-term, sustainable growth.
Materials and a recording of the presentations and Q&A will be made available on our website following the event.
If you would like to attend in person, please email djadeja@hikma.com.